Trial Profile
An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Uproleselan Administered Via the Intravenous Route to Healthy Subjects (ADME Study of IV [14C]-Uproleselan in Healthy Subjects)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Uproleselan (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Deep vein thrombosis; Multiple myeloma; Stem cell mobilisation
- Focus Pharmacokinetics
- Sponsors GlycoMimetics
- 13 May 2019 Status changed from active, no longer recruiting to completed.
- 22 Oct 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Aug 2018 New trial record